EUCTR2008-002109-38-DE进行中（未招募）不适用
A Phase 1b/2a, Open-Label, Multi-Center Study of AV-951 in Combination with Paclitaxel in Subjects with Advanced or Metastatic Breast Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for participation in the study:
- •1. = 18-year-old females
- •2. Histologically or cytologically documented invasive breast cancer
- •3. Documented progressive disease (Phase 1b study) OR documented metastatic disease (Phase 2a study)
- •4.Prior Treatment:
- •Phase 1b study: No more than 4 prior chemotherapy treatments, only 1 prior taxane-based regimen for metastatic disease. There is no limit to the number of prior hormonal or biological treatments.
- •Phaes 2a study: No prior chemotherapy or biological therapy for metastatic breast cancer. There is no limit to the number of prior hormonal treatments.
- •Prior adjuvant chemotherapy or biological therapy will not be counted in the number of prior treatments, unless recurrence occurs within 12 months of last dose of adjuvant therapy, in which case it will be counted as 1 prior therapy; adjuvant treatment with a taxane is allowed.
- •5.Measurable or evaluable disease by RECIST criteria (Phase 1b study) (see Appendix A). Subjects to be enrolled in the Phase 2a study are required to have measureable disease according to RECIST.
- •6.No prior VEGF-TKI drugs such as sunitinib, sorafenib, AZ2171, AG013736, GW786034, ZD6474 AMG706, PTK/ZK and other similar agents.
- •7.No treatment with bevacizumab within 4 weeks prior to start of protocol therapy, no prior treatment with other VEGF binding antibodies or VEGF-trap.
- •8. No treatment with the following agents within 3 weeks prior to start of protocol therapy:
- •Chemotherapy (at least 6 weeks for nitrosoureas, mitomycin C, and liposomal
- •doxorubicin)
- •Other signal transduction inhibitors and monoclonal antibodies
- •Immunotherapy or biological response modifiers
- •Any experimental therapy
- •9. No treatment with radiotherapy within 2 weeks (if involving < 25% of bone marrow), or 4 weeks (if involving = 25% of bone marrow) prior to start of protocol therapy.
- •10. Resolution of all toxicities associated with prior treatment to = Grade 1 (except for Grade 2 alopecia) prior to start of protocol therapy.
- •11. ECOG performance status = 2 and life expectancy = 3 months
- •12. Signed and dated written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects meeting any of the following criteria are ineligible for participation in the study:
- •1. Known hypersensitivity to paclitaxel or to any other component of the paclitaxel
- •formulation.
- •2. Pregnant or lactating women; all fertile subjects must use effective contraception (barrier method) while on study and for 3 months thereafter. All subjects must agree to use a highly effective method of contraception (including their partner). Effective birth control includes (a) IUD plus 1 barrier method, or (b) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm.) Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are not considered effective for this study.
- •3. Subjects with symptomatic CNS metastases. Subjects with treated brain metastases that have remained stable for at least 3 months without steroids are allowed. Subjects with signs or symptoms or history of brain metastasis must have a CT or MRI scan of the brain within 1 month prior to the start of protocol therapy. Subjects with spinal cord or nerve root compression who have completed treatment at least 4 weeks before the start of protocol therapy and are stable without steroid treatment for at least one week before start of protocol therapy are allowed. Subjects with leptomeningeal metastases are not allowed.
- •4. Any of the following hematologic abnormalities:
- •Hemoglobin < 9.0 g/dL
- •ANC < 1500 per mm3
- •Platelet count < 100,000 per mm3
- •5. Any of the following serum chemistry abnormalities:
- •Total bilirubin > 1.5 × ULN (>2.5 mg/dL in patients with Gilbert’s syndrome)
- •AST or ALT > 2.5 × ULN (or > 5 × ULN for subjects with liver metastasis)
- •GGT > 2.5 x ULN (or > 5 × ULN for subjects with liver metastasis)
- •Alkaline phosphatase > 2.5 × ULN (or > 5 × ULN for subjects with liver or bone
- •metastasis)
- •Serum albumin < 3.0 g/dL
- •Serum creatinine > 1.5 × ULN
- •Proteinuria > 2.5 g/24 hours or 3+ with urine dipstick
- •Any other = Grade 3 laboratory abnormality at baseline (other than those listed
- •6. Significant cardiovascular disease, including:
- •Clinically symptomatic heart failure.
- •Uncontrolled hypertension
- •7. Baseline neuropathy > Grade 1
- •8. Subjects with delayed healing of wounds, ulcers, and/or bone fractures
- •9. Serious/active infection or infection requiring parenteral antibiotics
- •10. Inadequate recovery from any prior surgical procedure; major surgical procedure within 6 weeks prior to start of protocol therapy.
- •11. Inability to comply with protocol requirements
- •12. Ongoing hemoptysis or history of clinically significant bleeding within 6 months to start of protocol therapy.
- •13. Cerebrovascular accident within 12 months to start of protocol therapy, or peripheral vascular disease with claudication on walking less than 1 block.
- •14. Deep venous thrombosis or pulmonary embolus within 6 months prior to start of protocol therapy.
- •15. Subjects with a currently active” second primary malignancy other than non-melanoma skin cancers. Subjects are not considered to have a currently active” malignancy if they have completed anti-cancer therapy and have been disease free for > 2 years.
- •16. Known concomitant genetic or acquired immune suppression disease such as HIV.
- •17. Treatment with systemic hormonal therapy within 3 weeks prior to start of or during proto
研究者
相似试验
进行中（未招募）
1 期
TL-895 and KRT-232 Study in Acute Myeloid LeukemiaRelapsed/Refractory (R/R) FLT3+ Acute Myeloid LeukemiaMedDRA version: 21.1Level: LLTClassification code 10081514Term: Acute myeloid leukemia refractorySystem Organ Class: 100000004864EUCTR2020-003109-73-DETelios Pharma, Inc.70
进行中（未招募）
1 期
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to RuxolitinibPrimary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF)MedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004554-29-ITKartos Therapeutics, Inc78
进行中（未招募）
1 期
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to RuxolitinibPrimary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF)MedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004554-29-DEKartos Therapeutics, Inc.36
进行中（未招募）
1 期
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to RuxolitinibEUCTR2019-004554-29-FRKartos Therapeutics, Inc.78
进行中（未招募）
1 期
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML)Relapsed or refractory AML, AML secondary to myeloproliferative neoplasms (MPN), and JAK2 mutationpositive AML.MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2019-001201-24-GBKartos Therapeutics, Inc.135